In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis.
New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR.
More than 5,000 women were interviewed about their eating habits from 1985 to 1991, and then researchers followed up with them 30 years later. The full study was published in Alzheimer’s and Dementia.
Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.
Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.
